Table 1.
Main characteristics of included studies
| Author | Year | Country | Sample
|
Stage (I + II/III) | Lymph node (0/+) | Grade (I + II/III) | ER status (−/+) | HER2 status (−/+) | |
|---|---|---|---|---|---|---|---|---|---|
| Normal | IDC | ||||||||
| Asiaf et al36 | 2014 | India | 128 | 128 | 89/39 | 79/49 | 108/20 | 39/89 | |
| Karray-Chouayekh et al37 | 2010 | Tunisia | 78 | 21/30 | 36/42 | 61/17 | 31/47 | 51/13 | |
| Hoque et al50 | 2009 | Italy | 12 | 45 | |||||
| Zou et al51 | 2009 | New Zealand | 19 | 20 | |||||
| Sunami et al52 | 2008 | USA | 130 | 102/8 | 76/54 | 65/65 | 78/29 | ||
| Prasad et al38 | 2008 | India | 50 | 15/35 | 27/23 | ||||
| Li et al53 | 2006 | Australia | 193 | 83/71 | 54/134 | 142/30 | |||
| Shinozaki et al27 | 2005 | USA | 10 | 151 | 102/43 | 37/114 | |||
| Caldeira et al54 | 2005 | Brazil | 71 | 53/18 | 53/18 | 45/26 | 63/8 | ||
| Hu et al55 | 2002 | People’s Republic of China | 23 | 18/5 | 15/8 | 5/10 | 10/3 | ||
| Toyooka et al28 | 2002 | USA | 10 | 51 | |||||
Abbreviations: ER, estrogen receptor; IDC, invasive ductal carcinoma.